moclobemide has been researched along with Migraine Disorders in 5 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "While on this therapy, 35 of the 42 migraine patients and 16 of the 17 patients with tension-type headache experienced good or very good improvement in their symptoms." | 5.30 | [Preventive treatment of migraine and chronic tension headache with moclobemide]. ( Amsler, F; Meienberg, O, 1997) |
| "Mean almotriptan AUC was higher (483 +/- 99." | 2.70 | Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ( Azie, NE; Bell, DJ; Burke, MT; Carel, BJ; Fleishaker, JC; Jansat, JM; Ryan, KK, 2001) |
| "Frequent and recurrent migraine headaches can, over time, pose the additional risks of stroke, brain damage, heart failure and attention deficit." | 1.33 | A chronopharmacological preventive treatment for sleep-related migraine headaches and chronic morning headaches: Nitric oxide supersensitivity can cause sleep-related headaches in a subset of patients. ( Eli, R; Fasciano, JA, 2006) |
| "While on this therapy, 35 of the 42 migraine patients and 16 of the 17 patients with tension-type headache experienced good or very good improvement in their symptoms." | 1.30 | [Preventive treatment of migraine and chronic tension headache with moclobemide]. ( Amsler, F; Meienberg, O, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eli, R | 1 |
| Fasciano, JA | 1 |
| Claman, JM | 1 |
| Meienberg, O | 2 |
| Amsler, F | 2 |
| Fleishaker, JC | 1 |
| Ryan, KK | 1 |
| Jansat, JM | 1 |
| Carel, BJ | 1 |
| Bell, DJ | 1 |
| Burke, MT | 1 |
| Azie, NE | 1 |
1 trial available for moclobemide and Migraine Disorders
| Article | Year |
|---|---|
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.
Topics: Adolescent; Adult; Cross-Over Studies; Drug Interactions; Female; Humans; Indoles; Male; Middle Aged | 2001 |
4 other studies available for moclobemide and Migraine Disorders
| Article | Year |
|---|---|
A chronopharmacological preventive treatment for sleep-related migraine headaches and chronic morning headaches: Nitric oxide supersensitivity can cause sleep-related headaches in a subset of patients.
Topics: Antioxidants; Headache Disorders; Humans; Hydrocortisone; Melatonin; Migraine Disorders; Moclobemide | 2006 |
The potential effectiveness of moclobemide, the new monoamine oxidase inhibitor, in the prophylaxis of migraine.
Topics: Adult; Benzamides; Female; Humans; Migraine Disorders; Moclobemide; Monoamine Oxidase Inhibitors | 1993 |
Moclobemide in the prophylactic treatment of migraine. A retrospective analysis of 44 cases.
Topics: Analgesics; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy | 1996 |
[Preventive treatment of migraine and chronic tension headache with moclobemide].
Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; | 1997 |